HC Wainwright Predicts Higher Earnings for BioLife Solutions

BioLife Solutions, Inc. (NASDAQ:BLFS) – Stock analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for BioLife Solutions in a research report issued on Friday, March 13th. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will post earnings per share of $0.01 for the quarter, up from their previous forecast of ($0.01). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q4 2026 earnings at $0.05 EPS and FY2026 earnings at $0.06 EPS.

Other research analysts have also issued research reports about the stock. Northland Securities set a $34.00 price target on shares of BioLife Solutions in a research report on Monday, January 5th. Zacks Research raised BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Wall Street Zen raised BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. Finally, UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $18.36 on Monday. The firm has a market cap of $886.79 million, a P/E ratio of -166.89 and a beta of 1.90. The firm’s 50-day simple moving average is $22.81 and its 200-day simple moving average is $24.83. BioLife Solutions has a twelve month low of $17.86 and a twelve month high of $29.62.

Insider Activity

In other BioLife Solutions news, insider Karen A. Foster sold 96,923 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $20.15, for a total value of $1,952,998.45. Following the transaction, the insider directly owned 113,742 shares in the company, valued at $2,291,901.30. The trade was a 46.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Troy Wichterman sold 990 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total transaction of $25,334.10. Following the sale, the chief financial officer directly owned 150,746 shares of the company’s stock, valued at approximately $3,857,590.14. The trade was a 0.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 101,956 shares of company stock valued at $2,068,241 over the last three months. 2.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. acquired a new stake in shares of BioLife Solutions in the first quarter valued at $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in BioLife Solutions by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock worth $489,000 after buying an additional 914 shares in the last quarter. Jane Street Group LLC bought a new stake in BioLife Solutions during the 1st quarter worth about $1,091,000. Strs Ohio acquired a new stake in BioLife Solutions in the 1st quarter valued at about $153,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in BioLife Solutions in the 2nd quarter valued at about $286,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.